LGI Homes Opens New Section at a Popular Community in the Houston Market
COVE, Texas, Sept. 17, 2020 (GLOBE NEWSWIRE) — LGI Homes, Inc. (Nasdaq:LGIH) announced it is now selling a new section […]
Passage Bio Announces Publication of Preclinical Gene Therapy Study Data from Frontotemporal Dementia Program
Data Show Single Injection of AAV-Granulin Gene Therapy into Central Nervous System Reverses Frontotemporal Dementia Pathology Caused by Granulin Mutations and […]
Chi-Med Announces Second NDA Acceptance in China for Surufatinib in Pancreatic Neuroendocrine Tumors
HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Sept. 17, 2020 (GLOBE NEWSWIRE) — Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: […]
Hygo Energy Transition Ltd. Launches Initial Public Offering
Golar LNG Limited (“Golar”) announces today that Hygo Energy Transition Ltd. (NASDAQ: HYGO) (“Hygo”), a joint venture with Stonepeak Infrastructure […]
Puyi Inc. to Announce Audited Financial Results For Fiscal Year 2020 and Host Conference Call on September 28, 2020
GUANGZHOU, China, Sept. 17, 2020 (GLOBE NEWSWIRE) — Puyi Inc. (“Puyi” or the “Company”) (NASDAQ: PUYI), a leading third-party wealth […]
Mersana Therapeutics Reports Updated Interim Data from the Ovarian Cancer Cohort of the XMT-1536 Phase 1 Expansion Study
– Maintained 34% objective response rate and 79% disease control rate, including two complete responses – XMT-1536 continues to be generally […]
Ruhnn to Participate in Upcoming September Investor Conferences
HANGZHOU, China, Sept. 17, 2020 (GLOBE NEWSWIRE) — Ruhnn Holding Limited (“ruhnn” or the “Company”) (NASDAQ: RUHN), a leading internet […]
BioNTech to Acquire GMP Manufacturing Site to Expand COVID-19 Vaccine Production Capacity in First Half 2021
Mainz, Germany, Sept. 17, 2020 (GLOBE NEWSWIRE) —Facility will become one of the largest mRNA manufacturing sites in Europe and […]
New Data from Ciforadenant Phase 1b/2 Clinical Study Presented at ESMO Virtual Congress 2020
Data is part of Genentech’s MORPHEUS umbrella program and covers patients with resistant/refractory NSCLC treated with ciforadenant in combination with […]
Genocea Presents Follow-up Data from GEN-009 Neoantigen Vaccine Phase 1/2a Trial at ESMO Virtual Congress 2020
Step-down responses to GEN-009, with 3 objective responses (2 PR, 1 CR) in the first 5 patients, suggests added benefit […]
